Morgan Stanley’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Morgan Stanley’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,549	Closed	-$44.4K	–	7773
2023 Q2	$44.4K	Sell	24,549 -150,835	-86%	-$276K	﹤0.01%	6257
2023 Q1	$232K	Buy	175,384 +155,272	+772%	+$254K	﹤0.01%	5643
2022 Q4	$34K	Sell	20,112 -31,591	-61%	-$40K	﹤0.01%	6455
2022 Q3	$95K	Buy	51,703 +7,576	+17%	+$22.6K	﹤0.01%	6106
2022 Q2	$135K	Buy	44,127 +41,364	+1,497%	+$253K	﹤0.01%	6111
2022 Q1	$20K	Buy	+2,763	New	+$27.2K	﹤0.01%	7161
2021 Q4	–	Sell	-99	Closed	-$1K	–	8210
2021 Q3	$1K	Buy	+99	New	+$983	﹤0.01%	7847
2021 Q2	–	Sell	-119	Closed	-$1K	–	7840
2021 Q1	$1K	Buy	+119	New	+$1.23K	﹤0.01%	7406

Other funds holding PRDS

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Morgan Stanley's PRDS Position: Q3 2023 in Review

Morgan Stanley sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 24,549 shares — an estimated $44.4K sold.

Morgan Stanley first reported a position in PRDS in Q1 2021 and held it in 8 quarters. The position peaked at $232K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Morgan Stanley reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 24,549 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $44.4K.
Morgan Stanley first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Morgan Stanley's Pardes Biosciences, Inc. Common Stock position peaked at $232K in Q1 2023.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.